ABC | Volume 114, Nº3, March 2020

Original Article Silva et al. Warfarin therapy in NVAF patients in Brazil Arq Bras Cardiol. 2020; 114(3):457-466 7. Björholt I,AnderssonS,NilssonGH,Krakau I.Thecostofmonitoringwarfarin in patients with chronic atrial fibrillation in primary care in Sweden. BMC Fam Pract. 2007 Feb 26;8:6. 8. Massaro AR, Lip GYH. Stroke prevention in atrial fibrillation: focus on Latin America. Arq Bras Cardiol. 2016;107(6):576-89. 9. de Lima Silva RG, Bertollo CM, Ferreira IG, Brant LC, Martins MAP. Assessment of oral anticoagulation control at two pharmacist-managed clinics in Brazil. Int J Clin Pharm. 2017;39(6):1157-61. 10. MartinsMAP, Costa JM, Mambrini JVM, Ribeiro ALP, Benjamin EJ, Brant LCC, et al. Health literacy and warfarin therapy at two anticoagulation clinics in Brazil. Heart. 2017;103(14):1089-95. 11. Pivatto Junior F, Scheffel RS, Ries L,Wolkind RR, Marobin R, Barkan SS , et al. SAMe-TT2R2 score in the outpatient anticoagulation clinic to predict time in therapeutic range and adverse events. Arq Bras Cardiol. 2017;108(4):290-6. 12. Assistência Médica Internacional [Internet]. São Paulo: Amil; 2018 [citado 6 mar.2018].Disponívelem: https://www.amil.com.br/portal/web/institucional. 13. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236-9. 14. World Health Organization (WHO) [internet]. International Statistical Classification of Diseases and RelatedHealth Problems 10th Revision (ICD- 10)-2015-WHO Version for 2015. [citado 10 jan. 2018]. Disponível em: http://apps.who.int/classifications/icd10/browse/2015/en#/I68 . 15. Schulman S, Angerås U, Bergqvist D, Eriksson B, Lassen MR, Fisher W, et al. Definition of major bleeding in clinical investigations of antihemostatic medicinalproducts insurgicalpatients.JThrombHaemost.2010;8(1):202-4. 16. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostaticmedicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692-4. 17. X-Rates. Brazilian Real Historical Rates Table. [citado 07 feb. 2018]. Disponível em: http://www.x-rates.com/historical/?from=BRL&amount= 1&date=2018-02-08. 18. Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, et al. Global and regional burden of stroke during 1990- 2010: findings from the Global Burden of Disease Study 2010. Lancet. 2014;383(9913):245-54. 19. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983-8. 20. Christensen MC, Valiente R, Sampaio Silva G, Lee WC, Dutcher S, Guimarães Rocha MS, et al. Acute treatment costs of stroke in Brazil. Neuroepidemiology. 2009;32(2):142-9. 21. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-67. 22. Cotté FE, Chaize G, Kachaner I, Gaudin AF, Vainchtock A, Durand-Zaleski I. Incidence and cost of stroke and hemorrhage in patients diagnosed with atrial fibrillation in France. J Stroke Cerebrovasc Dis. 2014;23(2):e73-e83. 23. White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med. 2007;167(3):239-45. 24. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118(20):2029-37. 25. Amin A, Deitelzweig S, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, et al. Estimation of the impact of warfarin’s time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials. J Thromb Thrombolysis. 2014;38(2):150-9. 26. Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation. 2013;127(22):2166-76. 27. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376(9745):975-83. 28. Singer DE, Hellkamp AS, Yuan Z, Lokhnygina Y, Patel MR, Piccini JP, et al. Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trial. J Am Heart Assoc. 2015;4(3):e001349. 29. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, HannaM, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92. 30. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91. 31. Ansell J, Hollowell J, Pengo V, Martinez-Brotons F, Caro J, Drouet L. Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulationmanagement (ISAM). J Thromb Thrombolysis. 2007;23(2):83-91. 32. Pokorney SD, SimonDN, Thomas L, FonarowGC, Kowey PR, Chang P, et al. Patients’ time in therapeutic range onwarfarin among US patients with atrial fibrillation: Results fromORBIT-AF registry. AmHeart J. 2015;170(1):141-8. 33. Deitelzweig S, Evans M, Hillson E, Trocio J, Bruno A, Tan W, et al. Warfarin time in therapeutic range and its impact on healthcare resource utilization and costs among patients with nonvalvular atrial fibrillation. Curr Med Res Opin. 2016;32(1):87-94. 34. Lopes RD, Guimarães PO, Kolls BJ, Wojdyla DM, Bushnell CD, Hanna M, et al. Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. Blood. 2017;129(22):2980-7. 35. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, DeenadayaluN, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants withwarfarin inpatientswithatrial fibrillation:ameta-analysisofrandomised trials. Lancet. 2014;383(9921):955-62. 36. Li XS, Deitelzweig S, Keshishian A, HamiltonM, Horblyuk R, Gupta K, et al. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice. A propensity-matched analysis of 76,940 patients. Thromb Haemost. 2017;117(6):1072-82. 465